Meeting
2019 ASCO Annual Meeting
Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).
Authors
Qiang Zhang
Northwestern University, Department of Medicine, Division of Hematology/Oncology, Lurie Cancer Center, Chicago, IL
Qiang Zhang , Lorenzo Gerratana , Ami N. Shah , Andrew A. Davis , Lisa E. Flaum , Youbin Zhang , Wenan Qiang , Amir Behdad , William John Gradishar , Leonidas C. Platanias , Massimo Cristofanilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1036)
DOI
10.1200/JCO.2019.37.15_suppl.1036
Abstract #
1036
Poster Bd #
117
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
First Author: Giuseppe Di Caro
Poster
2019 ASCO Annual Meeting
Genomic somatic alterations of human epidermal growth factor-2 (HER2) gene: A pan-cancer analysis.
First Author: Xinhua Zhu
Poster
2023 ASCO Annual Meeting
Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.
First Author: Esther G Chong
Poster
2023 ASCO Annual Meeting
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.
First Author: Angel Guerrero